CoChat

Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety

Open access
Rainer, Quentin, Xia, Lin, Guilloux, Jean-Philippe, Gabriel, Cecilia, Mocaër, Elisabeth, Hen, René, Enhamre, Erika, Gardier, Alain M., David, Denis J. · 2012 · The International Journal of Neuropsychopharmacology
Cited by 122

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Agomelatine (S20098) is a novel antidepressant drug with melatonergic agonist and 5-HT2C receptor antagonist properties, displaying antidepressant/anxiolytic-like properties in animal models and in humans. In a depression/anxiety-like mouse model in which the response of the HPA axis is blunted, we investigated whether agomelatine could reverse behavioural deficits related to depression/anxiety compared to the classical selective serotonin reuptake inhibitor, fluoxetine. Adult mice were treated for 8 wk with either vehicle or corticosterone (35 μg/ml.d) via drinking water. During the final 4 wk, animals were treated with vehicle, agomelatine (10 or 40 mg/kg i.p.) or fluoxetine (18 mg/kg i.p.) and tested in several behavioural paradigms and also evaluated for home-cage activity. Our results showed that the depressive/anxiety-like phenotype induced by corticosterone treatment is reversed by either chronic agomelatine or fluoxetine treatment. Moreover, agomelatine increased the dark/light ratio of home-cage activity in vehicle-treated mice and reversed the alterations in this ratio induced by chronic corticosterone, suggesting a normalization of disturbed circadian rhythms. Finally, we investigated the effects of this new antidepressant on neurogenesis. Agomelatine reversed the decreased cell proliferation in the whole hippocampus in corticosterone-treated mice and increased maturation of newborn neurons in both vehicle- and corticosterone-treated mice. Overall, the present study suggests that agomelatine, with its distinct mechanism of action based on the synergy between the melatonergic agonist and 5-HT2C antagonist properties, provides a distinct antidepressant/anxiolytic spectrum including circadian rhythm normalization.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1017/s1461145711000356

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 122

Metadata

Authors
Rainer, Q., Xia, L., Guilloux, J.-P., Gabriel, C., Mocaër, E., Hen, R., Enhamre, E., Gardier, A. M., & David, D. J.
Venue
The International Journal of Neuropsychopharmacology
Published
2011-04-08
Volume
15
Issue
03
Pages
321-335
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W2166636921
Cited by
122
References
12
FWCI
8.97
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety. https://app.cochat.ai/papers/10.1017/s1461145711000356
The paper
Rainer, Q., Xia, L., Guilloux, J.-P., Gabriel, C., Mocaër, E., Hen, R., Enhamre, E., Gardier, A. M., & David, D. J. (2012). Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety. The International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145711000356

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.